Alan Kay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alan Kay has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Fabien Zoulim
Hepatology Department, Hospices Civils de Lyon, University of Lyon, 69004 Lyon, France
3 shared publications Christian Trepo
INSERM U271, 151 cours A. Thomas, 69003 Lyon, France
2 shared publications- Alain Lachaux
Department of Pediatric Hepato-Gastroenterology and Nutrition, Femme-Mère-Enfants University Hospital, Hospices Civils de Lyon, Bron, France
1 shared publication Albert Tran
Service d'Hépato-Gastroentérologie, Hôpital de I'Archet 2, Nice, France
1 shared publicationBernard Mandrand
UMR2142 CNRS/bioMérieux, Ecole Normale Supérieure, Lyon, France
1 shared publicationDamien Jeantet
U271 INSERM, Lyon, France
1 shared publication
Latest Publications
- 1 August 2007
- Published by Elsevier in Virus Research
- Vol. 127 (2) , 164-176
Hepatitis B virus genetic variability and evolution
- 1 August 2007
- Published by Elsevier in Virus Research
- Vol. 127 (2) , 164-176
Hepatitis B virus genetic variability and evolution
- 1 June 2005
- Published by Microbiology Society in Journal of General Virology
- Vol. 86 (6) , 1687-1693
A quasi-monoclonal anti-HBs response can lead to immune escape of ‘wild-type’ hepatitis B virus
Hepatitis B virus (HBV) infections can be prevented or controlled by the host humoral immune response (anti-HBs) directed against the major surface antigen (HBsAg), elicited either naturally or by vaccination. A chronic HBV carrier was found to have high levels of both virus and anti-HBs. Full-length HBV genomes were amplified from the patient's serum, sequenced and cloned. The genome was ‘wild-type’ HBV of genotype C and serotypeadr. The sequence has remained stable, with no signs of emergence of an immune-escape mutant population. To study what was recognized by the patient's serum, viral particles were35S-labelled and then immunoprecipitated by using the patient's serum or control sera. The patient's serum immunoprecipitated theadrHBsAg encoded by his HBV genome poorly, but efficiently recognized HBsAg of serotypeayw. When his HBV genome was modified by a point mutation to express HBsAg of serotypeayr, the patient's serum could recognize the antigen, as well as the control anti-HBs-positive serum. The patient appeared to have made a quasi-monoclonal humoral response to theyepitope. By switching to thedepitope, which requires only a point mutation, the virus could replicate, despite the high levels of anti-HBs. This study underlines the subtleties of virus–host interactions. Implications for HBV vaccination are discussed.
- 1 June 2005
- Published by Microbiology Society in Journal of General Virology
- Vol. 86 (6) , 1687-1693
A quasi-monoclonal anti-HBs response can lead to immune escape of ‘wild-type’ hepatitis B virus
Hepatitis B virus (HBV) infections can be prevented or controlled by the host humoral immune response (anti-HBs) directed against the major surface antigen (HBsAg), elicited either naturally or by vaccination. A chronic HBV carrier was found to have high levels of both virus and anti-HBs. Full-length HBV genomes were amplified from the patient's serum, sequenced and cloned. The genome was ‘wild-type’ HBV of genotype C and serotypeadr. The sequence has remained stable, with no signs of emergence of an immune-escape mutant population. To study what was recognized by the patient's serum, viral particles were35S-labelled and then immunoprecipitated by using the patient's serum or control sera. The patient's serum immunoprecipitated theadrHBsAg encoded by his HBV genome poorly, but efficiently recognized HBsAg of serotypeayw. When his HBV genome was modified by a point mutation to express HBsAg of serotypeayr, the patient's serum could recognize the antigen, as well as the control anti-HBs-positive serum. The patient appeared to have made a quasi-monoclonal humoral response to theyepitope. By switching to thedepitope, which requires only a point mutation, the virus could replicate, despite the high levels of anti-HBs. This study underlines the subtleties of virus–host interactions. Implications for HBV vaccination are discussed.
- 18 June 2004
- Published by Wiley in Journal of Medical Virology
- Vol. 73 (4) , 508-515
Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays
Occult hepatitis B virus (HBV) infections show little or no serological markers of viral infection, including the absence of hepatitis B surface antigen (HBsAg) which is the main marker of ongoing HBV infection. Such infections can be important in the context of blood and/or organ donations. To study whether mutations contribute to HBsAg seronegativity, S gene sequences from such patients were amplified and cloned. Sequencing revealed 12 clones from seven different patients which contained potentially important mutations. The sequences were subcloned into an expression vector and mutant HBsAgs were expressed in cell culture. The capacity of three HBsAg detection assays to recognise the mutant HBsAgs was studied. Three categories were found: mutant HBsAgs that are not recognised by the assays, those that are recognised as well as wild-type (WT) antigen and an intermediate category where detection of the mutant HBsAgs is reduced with respect to WT. Most of the isolates fall into the second category. Mutations can therefore contribute to HBsAg seronegativity in occult HBV infections, but in most cases the explanation is probably the low level of viral replication. J. Med. Virol. 73:508–515, 2004.
- 18 June 2004
- Published by Wiley in Journal of Medical Virology
- Vol. 73 (4) , 508-515
Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays
Occult hepatitis B virus (HBV) infections show little or no serological markers of viral infection, including the absence of hepatitis B surface antigen (HBsAg) which is the main marker of ongoing HBV infection. Such infections can be important in the context of blood and/or organ donations. To study whether mutations contribute to HBsAg seronegativity, S gene sequences from such patients were amplified and cloned. Sequencing revealed 12 clones from seven different patients which contained potentially important mutations. The sequences were subcloned into an expression vector and mutant HBsAgs were expressed in cell culture. The capacity of three HBsAg detection assays to recognise the mutant HBsAgs was studied. Three categories were found: mutant HBsAgs that are not recognised by the assays, those that are recognised as well as wild-type (WT) antigen and an intermediate category where detection of the mutant HBsAgs is reduced with respect to WT. Most of the isolates fall into the second category. Mutations can therefore contribute to HBsAg seronegativity in occult HBV infections, but in most cases the explanation is probably the low level of viral replication. J. Med. Virol. 73:508–515, 2004.